ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Patient reported outcomes"

  • Abstract Number: 2002 • ACR Convergence 2024

    Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

    Laura Cappelli1, Cyd Eaton1, Yunzhi Wang1, Michelle Jones2 and Clifton Bingham3, 1Johns Hopkins School of Medicine, Baltimore, MD, 2Johns Hopkins School of Medicine, Pittsburgh, PA, 3Johns Hopkins University, Baltimore, MD

    Background/Purpose: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an impactful and often persistent side effect of cancer immunotherapy that can lead to permanent joint damage…
  • Abstract Number: 2180 • ACR Convergence 2024

    The Association Between Age at Diagnosis and Patient-Reported Outcomes in Patients with Vasculitis

    Jessica Bloom1, Kaci Pickett-Nairne2, Lori Silveira2, David Cuthbertson3, Carol McAlear4, Peter Merkel4 and Karen James5, and the Vasculitis Clinical Research Consortium, 1University of Colorado, Denver, CO, 2University of Colorado, Aurora, CO, 3University of South Florida, Tampa, FL, 4University of Pennsylvania, Philadelphia, PA, 5University of Utah, Salt Lake City, UT

    Background/Purpose: Vasculitis is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether the degree of this impact varies based…
  • Abstract Number: 2476 • ACR Convergence 2024

    The Impact of Systemic Sclerosis Manifestations on Survival and Humanistic Burden: A Targeted Literature Review

    vanessa smith1, Zoe Marjenberg2 and Elizabeth Volkmann3, 1Ghent University Hospital, Gent, Belgium, 2Maverex Ltd, North Shields, United Kingdom, 3University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles

    Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease with multiple disease manifestations, including cutaneous fibrosis, musculoskeletal inflammation, Raynaud phenomenon, calcinosis and digital ulceration. Internal…
  • Abstract Number: 0398 • ACR Convergence 2024

    Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data

    Mary Eckert1, Eveline Wu2, Melissa Oliver3, Joshua Scheck4, Sivia Lapidus5, Ummusen Kaya Akca6, Shima Yasin7, Aleksander Lenert8, Sara Stern9, Antonella insalaco10, Manuela Pardeo10, Gabriele Simonini11, Edoardo Marrani12, Xing Wang13, Bin Huang14, Leonard Kovalick15, Natalie Rosenwasser16, Erin Balay-Dustrude17, Gabriel Casselman16, Liau Adriel18, Ava Klein18, Yurong Shao4, Claire Yang4, Molly Briggs4, Emily Deng4, Iris Hamilton4, Ethan Mueller16, Elise Machrone4, Paige Trunnel4, Doaa Mosa19, Lori Tucker20, Hermann Girschick21, Ronald Laxer22, Georgina Tiller23, Jonathan Akikusa24, Christian Hedrich25, Karen Onel26, Fatma Dedeoglu27, Marinka Twilt28, Seza Ozen29, Polly Ferguson30, Laura Schanberg31, Bryce Reeve32 and Yongdong (Dan) Zhao33, 1Seattle Children's, Mercer Island, WA, 2University of North Carolina School of Medicine, Chapel Hill, NC, 3Indiana University, Indianapolis, IN, 4Seattle Children's Hospital, Seattle, 5Hackensack University Medical Center, Montclair, NJ, 6Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, 7University of Iowa Carver College of Medicine, Abu Dhabi, United Arab Emirates, 8University of Iowa, Iowa City, IA, 9University of Utah, Salt Lake City, UT, 10IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 11Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, 12University of Florence, Firenze, Florence, Italy, 13Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, 14Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, 15UNC Health Care, Durham, NC, 16Seattle Children's Hospital, Seattle, WA, 17University of Washington, Seattle, WA, 18Seattle Children’s Research Institute, University of Washington, Seattle, 19Mansoura University Hospital, Mansoura City, Egypt, 20BC Children's Hospital, Vancouver, BC, Canada, 21Vivantes Clinic Friedrichshain, Wuerzburg, Germany, 22SickKids, Toronto, ON, Canada, 23University of British Columbia - Vancouver, Vancouver, BC, Canada, 24Royal Children's Hospital, Parkville, Victoria, Australia, 25University of Liverpool, Liverpool, United Kingdom, 26HSS, New York, NY, 27Boston Children's Hospital, Boston, MA, 28Alberta Children's Hospital, Calgary, AB, Canada, 29Department of Pediatrics, Hacettepe University, Ankara, Turkey, 30University of Iowa Carver College of Medicine, Iowa City, IA, 31Duke University Medical Center, DURHAM, NC, 32Duke University School of Medicine, Durham, 33University of Washington, Redmond, WA

    Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. It is critical to capture the child’s health-related quality of life impact using validated patient-reported…
  • Abstract Number: 0623 • ACR Convergence 2024

    Select Patient Reported Outcome Measure Domains Enhance Immune Mediator Based Indexes That Inform Flare Risk and Disease Activity in Systemic Lupus Erythematosus

    Melissa Munroe1, Daniele DeFreese2, Adrian Holloway2, Mohan Purushothaman2, Wade DeJager3, Susan Macwana3, Joel Guthridge4, Stan Kamp3, Nancy Redinger3, Teresa Aberle4, Eliza Chakravarty4, Cristina Arriens4, Yanfeng Li5, hu Zeng5, Uma Thanarajasingam5, Judith James4 and Eldon Jupe2, 1Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, 2Progentec Diagnostics, Inc., Oklahoma City, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Mayo Clinic, Rochester

    Background/Purpose: We have recently validated a plasma Lupus Flare Risk Index (L-FRI; Munroe et al. Ann Rheum Dis. 2024. 83 [Supp 1]: 402) and Lupus…
  • Abstract Number: 1062 • ACR Convergence 2024

    Assessing Musculoskeletal Symptom Burden in a Cohort of Patients with Hidradenitis Suppurativa Using the IDEOM MSK-Q

    Gretchen Ball1, Hassan Hamade2, Sarah Romanelli2, Zachary Levy2, Lourdes Perez Chada3, Joseph Merola4 and Alice Gottlieb5, 1Albert Einstein College of Medicine, Ridgefield, CT, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 4UT Southwestern Medical Center, Newton, MA, 5Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA

    Background/Purpose: Hidradenitis suppurativa (HS) has been associated with inflammatory joint diseases such as psoriatic arthritis and ankylosing spondylitis.  Despite this correlation, dermatologists do not routinely…
  • Abstract Number: 1274 • ACR Convergence 2024

    Comparing Performance-Based Measures and Self-Reported Questionnaires for Assessment of Executive Function for Youth with Childhood-Onset Systemic Lupus Erythematosus

    Tala El Tal1, Jida Jaffan2, Justine Ledochowski3, Louise Boulard4, Oscar Mwizerwa2, Busisiwe Zapparoli5, Sarah Mossad6, Victoria Lishak7, Ibrahim Mohamed8, Joanna Law9, Lawrence Ng3, Paris Moaf9, Asha Jeyanathan2, Adrienne Davis10, Linda Hiraki3, Deborah Levy3, Ashley Danguecan11 and Andrea Knight12, 1The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, Canada, 4Neurosciences and Mental Health Program, SickKids Research Institute; The Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 5The Hospital for Sick Children, Etobicoke, ON, Canada, 6Hospital for Sick Children, Toronto, ON, Canada, 7The Hospital for Sick Kids, Toronto, ON, Canada, 8The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, 9The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 10Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 11The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, 12Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Executive dysfunction is common in childhood-onset systemic lupus erythematosus (cSLE). Comprehensive neuropsychological assessments use both performance-based measures and standardized questionnaires, capturing different cognitive constructs.…
  • Abstract Number: 1465 • ACR Convergence 2024

    The Use of Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease Questionnaire to Assess Patient Perceptions of Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast in a Phase 4 Trial

    Laure Gossec1, Laura Coates2, Dafna Gladman3, Alexis Ogdie4, Peter Nash5, Denis Poddubnyy6, Arthur Kavanaugh7, April Armstrong8, Carlo Selmi9, Ruben Queiro Silva10, Cynthia Deignan11, Rebecca Wang11, Jyotsna Reddy11, Michele Brunori11 and Philip Mease12, 1Sorbonne Université, Paris, France, 2University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, 6Charite-Universitatsmedizin Berlin, Berlin, Germany, 7University of California, San Diego, School of Medicine, La Jolla, CA, 8University of California Los Angeles, Los Angeles, CA, 9Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, 10Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, 11Amgen Inc., Thousand Oaks, CA, 12Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Oligoarticular psoriatic arthritis (PsA, ≤4 joints affected) is common but understudied, as most clinical trials enroll patients (pts) with ≥3 swollen and tender joints.…
  • Abstract Number: 2007 • ACR Convergence 2024

    Relationship Between Gout Flare Burden and Patient-Reported Outcome Following Allopurinol Initiation

    Lisa Stamp1, Chris Frampton1, Sarah Stewart2, Keith Petrie3, N Lawrence Edwards4, Angelo Gaffo5 and Nicola Dalbeth3, 1University of Otago, Christchurch, Christchurch, New Zealand, 2Auckland University of Technology, Auckland, New Zealand, 3University of Auckland, Auckland, New Zealand, 4University of Florida, Florida, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Gout flares are the most important clinical feature for people who have the disease. Given currently available treatment possibilities and limitations, low disease activity…
  • Abstract Number: 2188 • ACR Convergence 2024

    Parent Verses Patient Perspectives of Health-Related Quality of Life Among Children with Vasculitis

    Clare Peckenpaugh1, Aimee Hersh2, Sara Stern2, Erin Treemarcki2, Peter Merkel3 and Karen James2, 1University of Utah Department of Pediatrics, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Vasculitis is a group of chronic, relapsing diseases that can lead to significant morbidity due to both disease and treatment, impacting patients’ health related…
  • Abstract Number: 2555 • ACR Convergence 2024

    Addressing Economic Insecurities Could Improve Patient-Reported Outcomes in Lupus

    Shivani Garg1, Jay Patel1, Meredith Ingersoll2, Shelby Gomez2, Amanda Weber2, Sarah Panzer1, Sancia Ferguson3, Tripti Singh1 and Christie Bartels4, 1University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, 2UW Health, Madison, 3University of Wisconsin, Madison, Madison, WI, 4University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: A complex interaction between biologic factors and social determinants of health (SDoH) drives disparities in lupus (or SLE) outcomes in the US. A recent…
  • Abstract Number: 0405 • ACR Convergence 2024

    Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial

    Ekaterina Alexeeva1, Tatiana Dvoryakovskaya2, Elena Zholobova3, Elizaveta Krekhova4, Rinat Raupov5, Daria Bukhanova6, Alina Egorova6, Sofia Kuzkina6, Mikhail Samsonov6, Irina Nikishina7 and Mikhail Kostik5, 1National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, 2National Medical Research Center of Children's Health, Moscow, Russia, 3Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, 4National Medical Research Centre for Children's Health, Moscow, Russia, 5Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 6R-Pharm, Moscow, Russia, 7V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 inhibitor for treatment of rheumatoid arthritis and is being investigated in the open-label Phase 2 trial in adolescents…
  • Abstract Number: 0635 • ACR Convergence 2024

    Medical Record Natural Language Processing and Patient Biometric and Self-Reported Measures Inform an Artificial Intelligence Augmented Remote Care Management Strategy for Lupus Patients

    Gerald Lushington1, Bruce Wang2, Mohan Purushothaman3, Melissa Munroe4, Vijay R. Nadipelli5, Bernard Rubin2, Jessica Crawley2, Beth Valashinas6, Reshma Khan7, Anil Warrier8, Joseph Huffstutter9, Jennifer Murphy10, Lizeth Santamaria2, Sneha Nair2, Georg Armstrong2, Sandeep Nair2, Daniele DeFreese3, Adrian Holloway3, Arif Sorathia2, Brett Adelman2, Fabricio Pautasso2 and Eldon Jupe3, 1Progentec Diagnostics, Inc, Oklahoma City, OK, 2Progentec Diagnostics, Inc., Oklahoma City, OK, 3Progentec Diagnostics, Inc., Oklahoma City, 4Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, 5GSK, Medical Evidence Generation, Philadelphia, PA, 6Physicians Alliance of Connecticut, Milford, CT, 7Palm Beach Rheumatology and Wellness Center, Jupiter, FL, 8Millennium Rheumatology, Conroe, TX, 9Arthritis Associates PLLC, Signal Mountain, TN, 10Articularis Healthcare, Summerville, SC

    Background/Purpose: Systemic lupus erythematosus (SLE) is one of several rheumatologic disorders that presents frequent healthcare challenges, particularly for socioeconomic and geographically disadvantaged patients. Due to…
  • Abstract Number: 1183 • ACR Convergence 2024

    The Effectiveness of Orthosis for the Management of Hand Osteoarthritis-a Systemic Review and Meta-analysis

    Nouf Alhammadi1, Hanan Alqahtani2 and Bagrat Hakobyan3, 1HMG - Dr.Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia, 2University of toronto, Toronto, Canada, 3Independent researcher, Yerevan, Armenia

    Background/Purpose: Hand osteoarthritis (OA) affects  11-33% of men and women in their 50s and 60s, significantly affecting the quality of life of those afflicted.Orthoses are…
  • Abstract Number: 1275 • ACR Convergence 2024

    Implementing Integrated Mental Health Care in a Juvenile Myositis Clinic: A One-Year Review

    Luana Flores Pereira1, Louise Boulard2, Kayla M. Baker3, Audrey Bell-Peter4, Vanessa Carbone3, Brian Feldman5, Jayne MacMahon6, Valerio Maniscalco7, Jo-Anne Marcuz8, Tanya Slater4, Kristi Whitney4, Y. Ingrid Goh3 and Andrea Knight9, 1Neurosciences and Mental Health Program, SickKids Research Institute, Toronto, ON, Canada, 2Neurosciences and Mental Health Program, SickKids Research Institute; The Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 3Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Sciences, SickKids Research Institute, Toronto, ON, Canada, 4Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 5Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 6Division of Rheumatology, The Hospital for Sick Children; Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto; Child Health Evaluative Sciences, SickKids Research Institute, Toronto, ON, Canada, 7Rheumatology Unit, ERN-ReCONNET Center, Meyer Children Hospital IRCCS; Department of Pediatrics, Santo Stefano Hospital, Florence, Italy, 8Division on Rheumatology, The Hospital for Sick Children; Department of Rehabilitation Services, The Hospital for Sick Children, Toronto, ON, Canada, 9Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Juvenile myositis (JM) patients experience a high burden of emotional distress, yet mental health (MH) care is not typically integrated into standard clinical practices.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 43
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology